FIND, a co-op partner of the World Health Organization, has included Selfdiagnostics in their 2017-2020 project pipeline for tuberculosis diagnostics. Selfdiagnostics is one of the TOP 20 projects in the Sputum-based and drug susceptibility testing area that was given this priority status.
FIND has referenced Selfdiagnostics’ technology – a lab level accurate and fully disposable rapid self-test, in its tuberculosis (TB) pipeline. This test would allow end users to detect disease in a non-invasive, fast and convenient way. Tests in TB pipeline have advanced past the feasibility stage and therefore meet FIND’s priority diagnostic needs in order to fight tuberculosis (TB) in the world. Tuberculosis is one of the TOP 10 causes of death worldwide and diagnosing it remains a major challenge. The current “gold standard” test is smear microscopy, which omits too many cases and therefore simpler and more sensitive TB tests are urgently needed.
Currently our product for TB detection is estimated to be released at the beginning of 2019.
FIND is an international non-profit organization that enables the development and delivery of much-needed diagnostic tests for tuberculosis, malaria, HIV/AIDS, hepatitis C and several other infectious diseases. FIND has an active collaboration with the World Health Organization deciding and effectively implementing diagnostic solutions worldwide.
